INS and Stroke: We found a lower incidence of MACEs including nonfatal MI, nonfatal stroke, cardiac death, any death, amputation and heart failure for admission rate among the patients who received DPP4i-based therapy than in those treated with combined DPP4i- and insulin-based therapy.